3 Impacts of the CannTrust (TSX:TRST) Debacle

The fallout from CannTrust Holdings Inc’s (TSX:TRST)(NYSE:CTST) recent crisis could lead to tighter regulations and lower valuations for investors.

cup of cappuccino with a sad face

Image source: Getty Images

CannTrust Holdings (TSX:TRST)(NYSE:CTST) stock has been plummeting ever since it was revealed that the company sold unlicensed cannabis and circumvented regulations for selling legal marijuana. The stock has shed over three-fourths of its value since March, and it doesn’t seem like the end is in sight just yet. 

Reports suggest that the company was cultivating and selling unlicensed cannabis from the date of legalization to early March 2019 at a Niagara greenhouse that only received appropriate licences in April. The discovery prompted Health Canada to suspend CannTrust’s licences, which means it can no longer sell the 5,200 kilos of dried cannabis it has already harvested. 

Now heads are rolling. Chief executive Peter Aceto lost his job and one of the most lucrative pay packages in the marijuana industry, which included $8.4 million in stock options. The company has also asked Chairman Eric Paul to step down. Meanwhile, top officials are offloading their stakes in the company even as prices fall. 

Whether or not the company bounces back from this severe crisis is beside the point. The damage to the as-yet-nascent legal marijuana industry and the portfolios of its many stakeholders has already been done. Here are three lessons investors can walk away with.

The industry is facing a credibility issue

CannTrust isn’t the only cannabis producer facing a crisis. Major producers like Canopy Growth and Aphria have faced their own challenges this year. Both companies have lost their chief executive officers under dramatic circumstances. 

Allegations of overpaying for acquisitions and skirting regulations have dented the entire industry’s reputation. Marijuana now faces a credibility issue, which means investors must ask themselves if their own holdings could have some nasty surprises lurking underneath the surface. 

I believe investors can mitigate the risks by taking a closer look at the background and credibility of management teams. Potential conflicts, excessive compensation, or involvements in previous scandals should be immediate red flags for investors. 

Investors should also focus on tangible assets that can support valuations and help companies recover from scandal. Canopy Growth, for example, has $4.5 billion in cash on the books that can place a floor on the stock price if another crisis hits. 

Prepare for tighter marijuana regulations

It seems likely that government regulators like Health Canada will turn up the heat on the industry over the foreseeable future. Production facilities and financial transactions could come under closer scrutiny. This could raise the barriers to entry for the market and increase costs for producers.

Yet again, bigger players like Canopy could benefit. Higher barriers mean less competition and more room to grow. Meanwhile, premium cannabis producers with wider margins could absorb some of the added costs of tighter regulations. 

More modest valuations could be an opportunity

The ongoing chaos could finally deflate the valuations in the cannabis sector. It could be argued that valuations were too high ever since the prospect of legalization was raised. Now, however, the pendulum could swing the other way and some excellent companies could start trading below intrinsic value. 

Savvy investors should have no trouble finding attractive opportunities in this chaotic market. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Vishesh Raisinghani has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »